Overview

Detailed Summary

Anthem Biosciences Limited specializes in manufacturing specialty organic molecules and biologically active peptides, catering primarily to the drug and specialty chemicals industries.
The company reported a decline in quarterly revenue, with Q3FY26 showing a 15% year-over-year decrease compared to Q3FY25, while maintaining robust EBITDA margins around 41.8%.
Despite revenue challenges, Anthem focused on margin improvement, achieving an EBITDA growth of 22.6% for 9MFY26 compared to 9MFY25.
The strategic emphasis on backward integration and cost control is evident, as shown by a reduction in material costs, thus improving overall profitability.
Anthem's expanding scope into biosimilars and the strong performance of its CRDMO segment highlight its dedication to innovative biotech solutions.

Sector: Pharmaceuticals & Biotechnology
Industry: Biotechnology
Market Cap: 43,067 Cr
Volatility: Low Risk
P/E Ratio: 88.9
Industry P/E: 33.2
PEG Ratio: 2.4
P/B Ratio: 15.8
52W High: 873.25
52W Low: 579.45

Sales CAGR

1Y: 29.96%
3Y: 14.34%
5Y: 23.81%
10Y: —

Profit CAGR

1Y: 22.86%
3Y: 7.63%
5Y: 40.42%
10Y: —

ROE

TTM: 18.75%
3Y: 20.60%
5Y: 23.69%
10Y: —

ROCE

TTM: 26.49%
3Y: 26.83%
5Y: 31.08%
10Y: —

Technicals

‌

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Biotechnology

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
ABBOTINDIA		25931.95	54,155 Cr	35.53	13.50	1.86	37.62	48.38	26.77
ANTHEM		662.00	43,572 Cr	89.90	15.83	0.00	18.75	26.49	14.76
GLAXO		2451.80	40,166 Cr	39.34	23.52	2.28	55.94	74.64	27.86
IPCALAB		1439.00	39,115 Cr	42.99	5.27	0.26	13.33	17.89	7.73
AJANTPHARM		2895.85	35,046 Cr	34.54	8.12	1.00	22.56	27.85	17.89
JBCHEPHARM		1993.00	33,122 Cr	43.94	8.70	0.73	18.88	25.16	16.00
EMCURE		1680.70	32,853 Cr	37.77	6.93	0.17	16.72	19.37	9.53
Median: 7 Co.	—	1993.00	39,115 Cr	39.34	8.70	0.73	18.88	26.49	16.00

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	339	525	498	483	540	550	423
Expenses	218	330	338	288	349	332	266
Operating Profit	121	195	160	195	192	218	157
OPM %	35.71	37.19	32.04	40.40	35.45	39.62	37.15
Other Income	19	28	24	14	23	48	8.16
Interest	3.71	3.55	2.55	0.52	1.61	3.03	0.35
Depreciation	19	20	20	30	26	34	35
Profit Before Tax	118	200	161	178	186	230	130
Tax %	30.17	18.85	22.80	53.66	27.09	24.46	28.86
Net Profit	82	162	124	83	136	173	93
EPS in Rs	—	—	2.20	—	—	3.09	1.64

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	633	1,103	1,231	1,057	1,419	1,845
Expenses	451	696	666	628	914	1,174
Operating Profit	182	408	565	429	505	671
OPM %	28.75	36.96	45.89	40.58	35.58	36.37
Other Income	21	37	49	139	64	86
Interest	20	17	10	6.76	9.54	10
Depreciation	62	62	58	64	82	89
Profit Before Tax	121	366	546	497	477	657
Tax %	23.18	25.79	25.74	22.54	23.05	31.30
Net Profit	93	271	406	385	367	451
EPS in Rs	—	—	—	—	—	—
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	8.38	8.48	8.78	114	112	112
Reserves	413	693	1,346	1,627	1,813	2,298
Borrowings	121	100	35	126	239	113
Other Liabilities	245	232	228	148	235	284
Total Liabilities	787	1,034	1,619	2,014	2,398	2,808
Fixed Assets	306	361	329	449	483	705
CWIP	50	19	154	164	345	297
Investments	99	209	273	499	472	433
Other Assets	333	445	863	902	1,099	1,373
Total Assets	787	1,034	1,619	2,014	2,398	2,808

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	166	278	333	306	140	418
Cash from Investing Activity	-109	-196	-205	-376	-221	-152
Cash from Financing Activity	-48	-63	181	64	-77	-134
Net Cash Flow	8.53	18	308	-6.06	-158	133

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2024	Jul 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	77.23%	74.69%	74.69%	74.69%	74.68%
FIIs	0.00%	1.50%	1.67%	1.36%	1.28%
DIIs	22.77%	3.61%	7.22%	7.60%	11.55%
Public	0.00%	20.20%	16.42%	16.35%	12.50%
Total Shareholders	16	8,25,844	2,17,681	1,99,492	1,80,220

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Anthem Biosciences Ltd

Anthem Biosciences Ltd (ANTHEM) is currently trading at 766.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Anthem Biosciences Limited specializes in manufacturing specialty organic molecules and biologically active peptides, catering primarily to the drug and specialty chemicals industries. The company reported a decline in quarterly revenue, with Q3FY26 showing a 15% year-over-year decrease compared to Q3FY25, while maintaining robust EBITDA margins around 41.8%. Despite revenue challenges, Anthem focused on margin improvement, achieving an EBITDA growth of 22.6% for 9MFY26 compared to 9MFY25. The strategic emphasis on backward integration and cost control is evident, as shown by a reduction in material costs, thus improving overall profitability. Anthem's expanding scope into biosimilars and the strong performance of its CRDMO segment highlight its dedication to innovative biotech solutions.

Over the past 52 weeks, Anthem Biosciences Ltd has traded between a low of ₹579.45 and a high of ₹873.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Anthem Biosciences Ltd has a market capitalization of approximately 43,572.14. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Anthem Biosciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 89.90 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 43,572.14 Cr, Anthem Biosciences Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Anthem Biosciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Anthem Biosciences Ltd is 89.90. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The key announcement is the 'Biopharma Shakti' initiative, a program with a ₹10,000 crore outlay over five years to develop India as a global hub for biopharmaceutical manufacturing, focusing on biologics and biosimilars.

Anthem Biosciences Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Unlock more with professional

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock more with professional

Projection

Unlock more with professional

Documents

Actions

Announcements

AI Mode

Ask AI

Frequently Asked Questions about Anthem Biosciences Ltd

What is Anthem Biosciences Ltd share price today?

What does Anthem Biosciences Ltd do?

What is the 52-week high and low of Anthem Biosciences Ltd?

What is the market capitalization of Anthem Biosciences Ltd?

Should I consider investing in Anthem Biosciences Ltd stock?

Is Anthem Biosciences Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Anthem Biosciences Ltd belong to and why does it matter?

What is the PE ratio of Anthem Biosciences Ltd?

What is the main Union Budget 2026 announcement affecting Anthem Biosciences?

Investor’s Suite

Market Explorer

Market Pulse

Deep Dive

Utility

Company

Technicals

Forecasts

Unlock more with professional

Projection

Unlock more with professional

Frequently Asked Questions about Anthem Biosciences Ltd

What is Anthem Biosciences Ltd share price today?

What does Anthem Biosciences Ltd do?

What is the 52-week high and low of Anthem Biosciences Ltd?

What is the market capitalization of Anthem Biosciences Ltd?

Should I consider investing in Anthem Biosciences Ltd stock?

Is Anthem Biosciences Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Anthem Biosciences Ltd belong to and why does it matter?

What is the PE ratio of Anthem Biosciences Ltd?

What is the main Union Budget 2026 announcement affecting Anthem Biosciences?

Peers

Price Chart Comparison

Oscillators

Neutral

Overall

Bullish

Moving Averages

Bullish

Overall

Bullish

Announcements

Investment Checklist

Overview

Financial Ratios